Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.54 EUR | -0.92% | +6.82% | -24.26% |
Feb. 06 | FTSE 100 Closes Up 0.9%, Lifted by BP | DJ |
Feb. 06 | Novacyt says talks to sell Taiwan laboratory are terminated | AN |
Business Summary
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Number of employees: 120
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Primer Design
93.3
%
| 105 | 93.8 % | 23 | 93.3 % | -77.99% |
IT-IS International
6.7
%
| 11 | 9.7 % | 2 | 6.7 % | -84.60% |
Intercompany Eliminations
-0.1
%
| -9 | -8.3 % | 0 | -0.1 % | -99.86% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
48.1
%
| 50 | 44.6 % | 12 | 48.1 % | -76.14% |
America
21.3
%
| 11 | 9.5 % | 5 | 21.3 % | -50.39% |
Europe (Excluding United Kingdom)
18.3
%
| 38 | 33.9 % | 5 | 18.3 % | -88.06% |
Asia-Pacific
8.8
%
| 11 | 9.9 % | 2 | 8.8 % | -80.35% |
Middle East
1.8
%
| 1 | 0.7 % | 0 | 1.8 % | -47.11% |
Africa
1.7
%
| 1 | 1.3 % | 0 | 1.7 % | -71.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James McCarthy
CEO | Chief Executive Officer | 58 | 21-01-04 |
Steven Gibson
DFI | Director of Finance/CFO | 41 | 17-03-31 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 16-04-30 |
Mandy Cowling
IRC | Investor Relations Contact | - | 12-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Heath
BRD | Director/Board Member | 76 | 15-06-28 |
John Brown
BRD | Director/Board Member | 69 | 23-09-07 |
Lyn Rees
BRD | Director/Board Member | 51 | 23-09-07 |
Chairman | 58 | 14-09-30 | |
Founder | 73 | 06-07-02 | |
Juliet Thompson
BRD | Director/Board Member | 57 | 17-06-26 |
James McCarthy
CEO | Chief Executive Officer | 58 | 21-01-04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 70,626,248 | 68,226,800 ( 96.60 %) | 16,993 ( 0.0241 %) | 96.60 % |
Company contact information
Novacyt SAS
13 Avenue Morane Saulnier
78140, Vélizy-Villacoublay
+33 1 39 46 51 04
http://www.novacyt.comSector
Sales per Business
Sales per region
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.26% | 41.87M | |
+10.93% | 1.1B | |
-18.94% | 129M | |
+30.54% | 66.41M | |
+7.18% | 62.48M | |
+13.27% | 61.72M | |
-20.97% | 57.38M |
- Stock
- Equities
- Stock Novacyt - Euronext Paris
- Company Novacyt